ALEC
Alector, Inc. NASDAQ Listed Feb 7, 2019$1.83
Pre-mkt
$1.83
+0.00%
Mkt Cap $188.5M
52w Low $1.14
31.7% of range
52w High $3.32
50d MA $2.12
200d MA $2.06
P/E (TTM)
—
EV/EBITDA
—
P/B
6.2x
Debt/Equity
1.2x
ROE
-466.3%
P/FCF
-1.0x
RSI (14)
43.90
ATR (14)
$0.16
Beta
0.58
50d MA
$2.12
200d MA
$2.06
Avg Volume
752.2K
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
131 Oyster Point Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | AMC | -0.39 | -0.34 | +12.8% | 2.39 | -11.3% | +7.1% | -5.1% | -9.1% | -4.5% | +1.9% | — |
| Nov 6, 2025 | AMC | -0.42 | -0.34 | +19.0% | 1.30 | -2.3% | -1.5% | +2.3% | +3.8% | -1.5% | -10.4% | — |
| Aug 7, 2025 | AMC | -0.45 | -0.30 | +33.3% | 1.46 | +11.6% | +47.3% | +3.7% | -10.3% | +9.0% | +12.8% | — |
| May 8, 2025 | AMC | -0.44 | -0.41 | +6.8% | 1.04 | +0.0% | +12.5% | +2.6% | -7.5% | -3.6% | +3.7% | — |
| Feb 26, 2025 | AMC | -0.61 | -0.02 | +96.7% | 1.72 | +9.3% | -3.5% | -1.2% | -14.0% | +3.5% | +6.2% | — |
| Nov 6, 2024 | AMC | -0.53 | -0.43 | +18.9% | 5.24 | +0.4% | +7.6% | +2.0% | +5.4% | -8.4% | -7.6% | — |
| Aug 7, 2024 | AMC | -0.49 | -0.40 | +18.4% | 4.91 | +12.0% | +3.9% | -0.4% | +0.6% | -0.8% | -4.1% | — |
| May 8, 2024 | AMC | -0.48 | -0.38 | +20.8% | 5.19 | +0.8% | +0.2% | +1.0% | +2.7% | -1.1% | +6.0% | — |
| Feb 27, 2024 | AMC | -0.80 | -0.49 | +38.8% | 7.01 | -0.1% | -0.3% | -0.3% | +6.3% | -5.8% | -3.4% | — |
| Nov 7, 2023 | AMC | -0.65 | -0.53 | +18.5% | 5.75 | -3.5% | -7.3% | -9.1% | -7.1% | -16.2% | +14.1% | — |
| Aug 3, 2023 | AMC | -0.82 | 0.02 | +102.4% | 6.62 | +9.7% | +32.4% | -16.1% | +0.8% | +0.9% | +1.9% | — |
| May 4, 2023 | AMC | -0.75 | -0.55 | +26.7% | 6.72 | +3.3% | +10.3% | +7.0% | -0.3% | -4.2% | -2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $2.41 | $2.53 | +5.0% | +7.1% | -1.2% | +0.8% | +5.4% | -9.2% |
| Mar 10 | BTIG | Upgrade | Neutral → Buy | — | $2.19 | $2.39 | +9.1% | +8.7% | -2.5% | -3.9% | -1.3% | +0.5% |
| Oct 22 | William Blair | Downgrade | Outperform → Market Perform | — | $3.21 | $1.54 | -52.0% | -49.8% | -8.7% | +2.0% | +0.0% | +0.0% |
| Oct 22 | TD Cowen | Downgrade | Buy → Hold | — | $3.21 | $1.54 | -52.0% | -49.8% | -8.7% | +2.0% | +0.0% | +0.0% |
| Oct 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.21 | $1.54 | -52.0% | -49.8% | -8.7% | +2.0% | +0.0% | +0.0% |
| Oct 22 | BTIG | Downgrade | Buy → Neutral | — | $3.21 | $1.54 | -52.0% | -49.8% | -8.7% | +2.0% | +0.0% | +0.0% |
| Oct 22 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $3.21 | $1.54 | -52.0% | -49.8% | -8.7% | +2.0% | +0.0% | +0.0% |
| Sep 25 | BTIG | Maintains | Buy → Buy | — | $3.16 | $3.10 | -1.9% | -7.3% | +5.8% | -1.6% | -3.0% | +1.4% |
| Jul 28 | Mizuho | Upgrade | Neutral → Outperform | — | $1.76 | $1.91 | +8.5% | +0.0% | -8.5% | -0.6% | -6.9% | -2.7% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.04 | $1.04 | +0.0% | +12.5% | +2.6% | -7.5% | -3.6% | +3.7% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.72 | $1.88 | +9.3% | -3.5% | -1.2% | -14.0% | +3.5% | +6.2% |
| Dec 16 | Stifel | Downgrade | Buy → Hold | — | $1.97 | $1.87 | -5.1% | +0.5% | -4.5% | -5.8% | +0.0% | +4.5% |
| Nov 26 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $3.96 | $2.59 | -34.6% | -35.1% | -0.8% | +1.6% | -3.1% | +0.4% |
| Nov 26 | BTIG | Maintains | Buy → Buy | — | $3.96 | $2.59 | -34.6% | -35.1% | -0.8% | +1.6% | -3.1% | +0.4% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.24 | $5.26 | +0.4% | +7.6% | +2.0% | +5.4% | -8.4% | -7.6% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.26 | $4.27 | +0.2% | -1.6% | +9.1% | +0.4% | -5.0% | -0.9% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.19 | $5.23 | +0.8% | +0.2% | +1.0% | +2.7% | -1.1% | +6.0% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.01 | $7.00 | -0.1% | -0.3% | -0.3% | +6.3% | -5.8% | -3.4% |
| Dec 14 | Stifel | Upgrade | Hold → Buy | — | $6.90 | $7.88 | +14.2% | +15.9% | +3.5% | -1.4% | +2.8% | -6.1% |
| Nov 17 | Mizuho | Maintains | Buy → Buy | — | $3.94 | $3.98 | +1.0% | +9.4% | +14.2% | -2.8% | +1.3% | +3.7% |
| Aug 11 | Mizuho | Maintains | Buy → Buy | — | $7.63 | $7.58 | -0.7% | -2.2% | +0.5% | -0.3% | -4.5% | -1.3% |
| Aug 8 | Stifel | Maintains | Hold → Hold | — | $7.36 | $7.27 | -1.2% | +0.8% | +0.9% | +1.9% | -2.2% | +0.5% |
| Aug 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.77 | $8.41 | -4.1% | -16.1% | +0.8% | +0.9% | +1.9% | -2.2% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.62 | $7.27 | +9.7% | +32.4% | -16.1% | +0.8% | +0.9% | +1.9% |
| May 5 | Barclays | Maintains | Overweight → Overweight | — | $6.72 | $6.94 | +3.3% | +10.3% | +7.0% | -0.3% | -4.2% | -2.9% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.72 | $6.94 | +3.3% | +10.3% | +7.0% | -0.3% | -4.2% | -2.9% |
| Mar 3 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.24 | $8.36 | +1.5% | -4.2% | -7.9% | -0.7% | -0.1% | -0.7% |
| Mar 2 | BTIG | Maintains | Buy → Buy | — | $8.80 | $8.65 | -1.7% | -6.4% | -4.2% | -7.9% | -0.7% | -0.1% |
| Mar 1 | Citigroup | Maintains | Buy → Buy | — | $8.54 | $8.42 | -1.4% | +3.0% | -6.4% | -4.2% | -7.9% | -0.7% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.54 | $8.42 | -1.4% | +3.0% | -6.4% | -4.2% | -7.9% | -0.7% |
| Jan 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.44 | $8.36 | -0.9% | +1.5% | +2.7% | +1.9% | +2.1% | -5.7% |
| Nov 10 | Citigroup | Maintains | Buy → Buy | — | $6.88 | $7.30 | +6.1% | +19.6% | +5.6% | -1.4% | +0.9% | -1.8% |
| Sep 9 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $10.99 | $10.06 | -8.5% | -12.4% | +5.7% | -9.1% | +4.8% | +1.3% |
| Jul 11 | Citigroup | Maintains | Buy → Buy | — | $11.37 | $11.17 | -1.8% | -7.4% | +6.9% | +3.3% | -4.9% | +0.0% |
| Jul 7 | Mizuho | Maintains | Buy → Buy | — | $11.56 | $11.93 | +3.2% | -0.6% | -1.0% | -7.4% | +6.9% | +3.3% |
| May 24 | Goldman Sachs | Maintains | Sell → Sell | — | $9.24 | $9.00 | -2.6% | -4.9% | +0.8% | +0.3% | +3.5% | -3.7% |
| May 11 | Barclays | Maintains | Overweight → Overweight | — | $8.16 | $8.04 | -1.5% | -6.2% | +7.1% | +5.3% | +0.1% | +5.6% |
| Apr 13 | Goldman Sachs | Maintains | Sell → Sell | — | $12.49 | $11.81 | -5.4% | -1.4% | -6.9% | -4.1% | +3.2% | -0.4% |
| Mar 8 | Stifel | Downgrade | Buy → Hold | — | $14.85 | $13.35 | -10.1% | -9.7% | +12.5% | -2.3% | -5.0% | -3.4% |
| Feb 25 | Citigroup | Maintains | Buy → Buy | — | $16.15 | $17.29 | +7.1% | -0.9% | -1.0% | -2.2% | -1.3% | -0.9% |
| Sep 27 | William Blair | Maintains | Outperform → Outperform | — | $23.60 | $24.10 | +2.1% | +1.7% | -2.3% | +0.2% | -2.8% | +3.9% |
| Aug 3 | Goldman Sachs | Maintains | Buy → Buy | — | $25.34 | $25.31 | -0.1% | +1.8% | +7.6% | +3.1% | -3.4% | -2.9% |
| Jul 16 | Morgan Stanley | Maintains | Overweight → Overweight | — | $33.40 | $33.80 | +1.2% | -0.9% | -5.5% | +4.0% | -6.9% | +4.9% |
| Apr 19 | Morgan Stanley | Maintains | Overweight → Overweight | — | $17.80 | $17.57 | -1.3% | +0.3% | +0.8% | +0.6% | +4.4% | -0.7% |
| Jul 29 | Barclays | Maintains | Overweight → Overweight | — | $21.34 | $16.45 | -22.9% | -23.6% | +2.9% | -6.6% | -1.2% | -3.0% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.02 | $31.04 | +0.1% | -5.2% | -3.9% | -14.1% | -3.3% | +4.0% |
| Jun 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $30.56 | $30.98 | +1.4% | -0.8% | -1.1% | +3.0% | +0.6% | +0.4% |
| Apr 28 | Goldman Sachs | Maintains | Buy → Buy | — | $26.40 | $27.19 | +3.0% | -2.1% | +8.9% | -12.2% | -2.2% | +6.1% |
| Apr 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $23.49 | $22.97 | -2.2% | -5.2% | +1.0% | +8.0% | +3.5% | -4.8% |
| Mar 6 | Citigroup | Maintains | Buy → Buy | — | $29.45 | $29.04 | -1.4% | -1.2% | -10.2% | +3.4% | -7.8% | -15.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Wong-Sarad Grace | Principal Accounting Officer | Sell | 3,475 | $1.88 | $7K | 95,461 | +1.69% | -6.75% |
| Jun 2, 2026 | Berkley Neil Lindsay | CFO & Chief Business Officer | Sell | 19,360 | $1.97 | $38K | 379,900 | +1.69% | -6.75% |
| Jun 2, 2026 | Wong-Sarad Grace | Principal Accounting Officer | Sell | 5,709 | $1.97 | $11K | 98,936 | +1.69% | -6.75% |
| Jun 2, 2026 | Rosenthal Arnon | Chief Executive Officer | Sell | 87,216 | $1.97 | $172K | 2,367,206 | +1.69% | -6.75% |
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Acadian Asset Management Llc | 4,038,785 | $9M | Added | Mar 2026 |
| 2 | Foresite Capital Management Iv, Llc | 3,887,200 | $8M | — | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 3,678,722 | $8M | New | Mar 2026 |
| 4 | D.e. Shaw & Co | 3,332,835 | $7M | Added | Mar 2026 |
| 5 | Vanguard Portfolio Management Llc | 2,583,542 | $6M | New | Mar 2026 |
| 6 | Millennium Management | 1,979,226 | $4M | Added | Mar 2026 |
| 7 | Fmr Llc | 1,796,104 | $4M | Reduced | Mar 2026 |
| 8 | Medici Capital Llc | 1,652,520 | $4M | Added | Mar 2026 |
| 9 | Renaissance Technologies Llc | 1,287,691 | $3M | Reduced | Mar 2026 |
| 10 | Two Sigma Investments, Lp | 1,279,306 | $3M | Added | Mar 2026 |
| 11 | Deerfield Management Company, L.p. | 1,055,192 | $2M | — | Mar 2026 |
| 12 | Adar1 Capital Management, Llc | 1,050,000 | $2M | New | Mar 2026 |
| 13 | Jane Street Group, Llc | 993,913 | $2M | Added | Dec 2025 |
| 14 | Aqr Capital Management Llc | 711,334 | $2M | Added | Mar 2026 |
| 15 | Northern Trust Corp | 692,256 | $1M | Added | Mar 2026 |
| 16 | Marshall Wace, Llp | 620,424 | $1M | Reduced | Mar 2026 |
| 17 | Panagora Asset Management Inc | 590,388 | $1M | Reduced | Mar 2026 |
| 18 | Morgan Stanley | 638,144 | $996K | Reduced | Dec 2025 |
| 19 | Eversource Wealth Advisors, Llc | 40,827 | $979K | Added | Mar 2026 |
| 20 | Bank Of America Corp /de/ | 380,908 | $819K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$188.5M
Enterprise Value
-$40.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.09x
P/B
6.15x
P/S
10.23x
P/FCF
-1.02x
EV/EBITDA
—
Shares Out
103.0M
Financials (TTM)
Revenue
$18.4M
Net Income
-$125.4M
EBITDA
-$116.4M
Free Cash Flow
-$184.1M
Op Cash Flow
-$184.0M
EPS Basic
$-1.39
EPS Diluted
$-1.19
EPS Forward
$-0.92
Gross Margin
-61.2%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$293.2M
Total Liab.
$262.6M
Total Equity
$30.6M
Cash
$256.0M
LT Debt
$26.8M
Book Value/Sh
$0.30
Debt/Equity
1.18x
Current Ratio
3.83
Quick Ratio
3.83
Returns & Growth
ROE
-466.3%
ROA
-48.7%
ROIC
-62.5%
Rev Growth YoY
-79.1%
EPS Growth YoY
-13.0%
Price Returns
2W
-6.1%
1M
-8.9%
3M
-11.1%
6M
+62.4%
12M
+62.4%
Technicals
52W High
$3.32
52W Low
$1.14
50d MA
$2.12
200d MA
$2.06
RSI (14)
43.90
ATR (14)
$0.16
Beta
0.58
Avg Volume
752K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$3.50
High
$5.00
Low
$1.50
Median
$4.00
Data updated apr 24, 2026 5:11pm
· Source: financialmodelingprep.com